PDCD1 and non-small cell lung carcinoma: Several clinical studies have demonstrated the clinical activity of anti-PD-1/anti-PD-L1 agents in various tumors, including non-small cell lung cancer (NSCLC), melanoma, and Hodgkin lymphoma [16–18].